No Data
No Data
Insider Sellers Might Regret Selling Apellis Pharmaceuticals Shares at a Lower Price Than Current Market Value
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Apellis Pharmaceuticals Analyst Ratings
UBS Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $45